Mount Sinai Network of Excellence in Neuroscience Clinical Trials is one of the 25 specialized clinical centers included in the The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT).

NeuroNEXT is funded by the National Institutes of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS) and targets people with neurological disorders, in both the adult and pediatric populations.  The Network includes a CCC, a DCC and 25 Clinical Sites, all with specialties in Neurology including a broad range of neurological disorders except for stroke (see StrokeNet) and Alzheimer’s Disease.

NeuroNEXT encourages researchers who are considering a Phase II clinical study, but do not have the experience nor the resources to conduct one, to apply through the NeuroNEXT program.  With 25 sites in the network, they could provide equipment, standardize data acquisition and provide analysis. Also, patient recruitment time is greatly reduced with 25 sites enrolling simultaneously.

Neurology Divisions participating in NeuroNEXT

The Mount Sinai Health System Department of Neurology has a wide range of divisions geared to education, research, and patient care that are included in the Sinai NeuroNEXT initiative. Blending these functions is instrumental to improving outcomes in the treatment of movement disorders, multiple sclerosis, epilepsy, headache, neuromuscular disorders, brain and spinal cord tumors, and other neurological disorders in children and adults.

The Icahn School of Medicine at Mount Sinai presents a rich environment for early stage investigators to be exposed to and develop additional research and clinical trial skills in the NeuroNEXT Fellowship Program .

How to Apply for a NeuroNEXT Grant 

Anyone can apply for a NeuroNEXT Grant. NeuroNEXT has several funding mechanisms for academic and industry partners, and you do not have to be based at a NeuroNEXT site to submit. The first step is to complete the NeuroNEXT Clinical Study Concept Synopsis. Before you submit your proposal to the NeuroNEXT Network, please contact the Mount Sinai principal investigators (PIs) Aaron Miller, MD and Adilia Hormigo, MD and director of career enhancement Nathalie Jette, MD and program coordinator Ruthie Perez to schedule a meeting to discuss your proposal. 

NeuroNext Principal Investigators

Aaron Miller, MD

Adilia Hormigo, MD, PhD

NeuroNEXT Co-Investigators

John Crary, MD, PhD

Kristen Dams-O’Connor, PhD

Michelle Fabian, MD

Noam Harel, MD, PhD

Matilde Inglese, MD, PhD

Joanna Jen, MD, PhD

Nathalie Jette, MD, MSc, Director of Career Enhancement

Harriet Kang, MD

Ilana Katz-Sand, MD

Sylvia Klineova, MD, MS

Stephen Krieger, MD

Mark Kupersmith, MD

Benjamin Natelson, MD

Jessica Robinson-Papp, MD, MS

Stephen Scelsa, MD

David Simpson, MD

James Sumowski, PhD

Winona Tse, MD

Currently Active NeuroNEXT Studies

Topiramate as a Disease Altering Therapy for CSPN (Cryptogenic Sensory Peripheral Neuropathy)

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with GNE Myopathy